Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

CompletedOBSERVATIONAL

Enrollment

98,947

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions

Pulmonary Embolism

Interventions

DRUG

Rivaroxaban

Any rivaroxaban dispensing claim is used as the exposure group

DRUG

Warfarin

Any warfarin dispensing claim is used as the reference group

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04879407 - Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter